Patients sometimes experience adverse drug reactions for both efficacy and safety of a given drug regimen and (ADR) leading to deterioration of their underlying this is the central topic of pharmacogenomics. Drug condition in clinical practice. Physiology of individual development and pretreatment genetic analysis of patients patient can vary, so the response of an individual to drug will be two major practical aspects in pharmacogenomics. therapy may also be highly variable. This is a major Highly specialized drug research laboratories will achieve clinical problem, since this inter-individual variability is the first goal, while the second goal has to be achieved until now only partly predictable. Besides these medical by clinical laboratories 2, 3 . problems, cost-benefit calculations for a given pharmacological therapy will be affected significantly.
Drug development: This is exemplified by a recent US study, which estimates There are two pharmacogenomic approaches. First, for that over 100,000 patients die every year from ADRs 1 .
most therapies a correct diagnosis is mandatory for a satisfactory therapeutic result. This is more relevant There are many factors such as age, sex, nutritional because many diseases may be caused by different status, kidney and liver function, concomitant diseases and genetic defects or be significantly affected by the genetic medications, and the disease that affects drug responses.
background of an individual. Thus, phenotypically similar In recent years, it has become clear that genetic factors disease states may have quite different underlying significantly modify drug responses. These factors should pathobiochemical mechanisms e.g., the therapy of M3 be evident for the physician.
AML (promyelocytic leukemia) with retinoids. A small subgroup of patients carries an unusual chromosomal The first examples include hemolysis in patients with glucose-6-phosphate dehydrogenase deficiency when administered antimalarial drugs and severe prolonged muscle relaxation with suxamethonium in patients with cholinesterase deficiency. This has been supplemented by numerous polymorphisms in drug-metabolizing enzymes, cellular receptors, transporters and plasma proteins. It is important to note that most of these polymorphisms or defects do not manifest themselves as a phenotype without a pharmacological challenge. Thus, the genetic constitution of an individual is extremely relevant *For correspondence E-mail: tripathi.pushpendra@rediffmail.com rearrangement-t(11;17)(q23;q21), leading to a PLZF/RARA rather than the typical PML/RARA fusion gene 4 . These patients are retinoid-resistant and will perhaps need other treatments. Thus, a better classification and understanding of disease mechanisms will be the basis for a targeted development of new drugs.
Second approach, the response of an individual to a specific therapy may depend on the genes interacting with drug metabolism and/or action. The first genes shown to affect outcome of therapies coded for enzymes that are involved in the metabolism of drugs. These are very obvious targets for pharmacogenomic studies. The best-investigated examples were the cytochrome P450 www.ijpsonline.com enzymes and N-acetyltransferase 5 . In the cytochrome P450 system, there are examples for drug toxicity related to poor metabolism or even complete lack of metabolism, as well as for reduced drug efficacy due to ultra rapid metabolism. It is estimated that more than one half of all currently used drugs are metabolized by P450 enzymes, and that CYP3A4 accounts for roughly 50% of these, followed by CYP2C6 (20%), and CYP2C9 and CYP2C19 (15%) 5 . CYP2C6, CYP2C9, CYP2 C 19, and CYP2A6 have been shown to be functionally polymorphic 6 . At present, drug development tries to avoid substances Pharmacogenomics as diagnostic tool in clinical therapeutics: Much more relevant for laboratory medicine is the analysis of genetic polymorphisms in patients before therapy. With the expansion of our knowledge about gene-drug interactions the number of diagnostic tests will increase rapidly. The typical questions here relate to the risk for ADRs, and potential therapy failures.
At present, the most widely used tests apply to the detection of patients that might experience severe or even whose metabolic pathways are significantly influenced by life-threatening toxicity from a certain drug. Usually, this is polymorphisms in P450 enzymes. However, with the more associated to deficient activity of an enzyme that is widespread availability of clinical tests, this may no longer involved in the metabolism and/or inactivation of a drug. be necessary. While genetic polymorphisms may
The consequence is prolonged and exaggerated drug significantly affect the metabolism of drugs via P450 action. Probably one of the most widespread assays is the enzymes, it should be kept in mind that drug-drug analysis of thiopurine-methyltransferase (TPMT) activity. interactions in genetically normal individuals play a
The polymorphism of TPMT has been described about 25 similarly important role, as can be seen for example in years ago by Weinshilboum and Sladek 17 , its association the severely increased risk for toxicity if statins modified with azathioprine toxicity was detected only a little over 15 by CYP3A4 are co-administered with drugs inhibiting years ago
18
, and broad interest in the pharmacogenetic trait CYP3A4, as for instance, mibefradil.
has developed only in the mid 90s. The rationale whether a genetic or a biochemical test should be used to analyse In the long run, genes coding for receptors or signaling TPMT is summarised in the paragraph on methodology, molecules involved in the pathophysiology of disease will because it may be taken as a paradigm for most if not all be perhaps of broader relevance. G-protein-coupled pharmacogenetic tests. The major considerations relate to receptors are a good example to illustrate this point.
sensitivity, specificity and cost effectiveness. TPMT also Several receptor genes from this family including the ß 1 . Such ligand-independent receptors underlie several human diseases, e.g., thyroid adenoma 13 , precocious puberty 14 , and Jansen's metaphyseal chondrodysplasia 15 . Overall, pharmacogenomic approaches offer interesting perspectives for molecular design and development of more specific drugs with significant benefits to patients 16 . tricyclic antidepressants, proarrhythmic effects of antiarrhythmic drugs. Decreased activity of CYP2C9 can lead to bleeding under warfarin or tolbutamide therapy. Increased effects of diazepam may accompany defects in CYP2C19. A recent study suggests that a poor-metaboliser status for CYP2C19 (CYP2C19*2) may be associated with an increased risk for ventricular tachycardias and torsade de pointes-arrhythmias under treatment with terodiline, an anticholinergic agent with Ca-blocking activity 19 . Terodiline has been implicated to cause QT prolongation and life-threatening arrhythmias. If this association is confirmed, one might be able to reduce the incidence of such potentially lethal complications by genetic tests of patients before treatment. www.ijpsonline.com
One of the major areas in which polymorphic P450 enzymes are relevant, are psychiatric diseases. Especially, polymorphisms in CYP2D6 may significantly affect drug levels of antipsychotic and antidepressant medications. Even though this could be predicted by genetic analysis, the usual approach here is not testing of pharmacogenetic polymorphisms but rather regular determinations of drug levels. This will not only provide plasma levels in relation to drug dose, but also permit monitoring of compliance with the prescribed drug 20 . Altered metabolism of substances by P450 enzymes can be predicted by analysis of the polymorphisms for pharmacotherapy is still very limited. To improve this, it will be mandatory to accompany clinical drug trials with genotype analysis of the probands. This can be either performed by analyzing candidate genes of potential relevance or by genome-wide single nucleotide polymorphism (SNP) analysis. The candidates identified by this approach can be sequenced and analyzed for polymorphic markers that can be included in clinical trials. At current prices, the costs for a genomewide SNP analysis in a drug trial have been estimated to be probably far above 10 US $ million. Thus, genomemetabolism of test substances or by genotyping. While wide analyses will be the exception in drug trials as long genotyping never achieves 100% sensitivity and does not as the technology does not improve significantly. One take into account drug-drug interactions, it is much easier to improvement could be allele discrimination by identifying perform, is not confounded by any underlying disease, and haplotypes. This has been impossible with the current carries no risk of adverse reactions to the test substances 21 .
PCR-based techniques for SNP detection, but would At present, there is no general consensus which patients reduce the number of SNPs needed significantly 25 should be tested for P450 polymorphisms. Candidates are patients with poor therapeutic responses despite optimal As outlined above, pharmacogenetic trials will be most dosing, or patients with a relative that had ADRs to one of important for drugs with a high risk for severe ADRs and the drugs metabolised by a polymorphic P450 enzyme. As a narrow therapeutic range, e.g., immunosuppressive or outlined above, in the future more drugs may be cytostatic drugs. However, as exemplified with the P450 developed that are affected by P450 polymorphisms and enzymes, there are genetic polymorphisms that solely require testing of a patient before institution of therapy. In affect plasma levels of a drug. If this drug has a narrow this case, laboratories must be prepared to perform routine therapeutic range, the consequence may be that drug tests for P450 polymorphisms.
monitoring rather than genetic tests prior to therapy will be performed. Pharmacogenetics will be also important Another major problem for clinical utility and acceptance for long-term treatments, whose outcome can be only of a pharmacogenetic test are impracticability. At present, predicted after years of treatment. In this case, it will be few convincing examples for short therapeutic trials are important to identify patients that will not respond to available. It has been shown that a common polymorphism treatment early on to optimize the risk-benefit and the in the gene for cholesteryl ester transfer protein (CETP) cost-benefit ratios of treatment. Therefore, therapeutic is associated with the effect of pravastatin on the interventions that fall into one of these categories are progression of coronary atherosclerosis 22 . However, the predictably the first that will be assessed in reported association of the apolipoprotein E polymorphism pharmacogenetic trials. with the response to treatment with tacrine 23 is a good example for a spurious genetic association. It is a good Methodology:
. reminder of the general problems observed with For clinical analysis of pharmacogenetically relevant association studies that are well known from many trials 24 .
polymorphisms or mutations, several approaches can be taken. Pharmacologic approaches are usually not feasible Besides these strictly clinical considerations, the classic in the clinical routine setting, because they require test diagnostic characteristics of the test applied will be doses of the drug or a compound supposed to have the important, i.e., its specificity, sensitivity and predictive same metabolism followed by serial determinations of value of a positive and/or negative test. The latter is blood levels of the drug and/or metabolites. There are obviously related to the prevalence of the polymorphism few commonly used tests, e.g., the caffeine test to identify or gene defect in the population. These properties of a the NAT-2 phenotype, however, it may be expected that diagnostic test will determine its cost effectiveness. And these tests are substituted by genetic tests or enzyme finally, it will be relevant for assay development whether activity determinations. If enzyme activity is a critical the therapeutic regimen in question is common or rare.
factor and related to gene polymorphisms (e.g., TPMT), it may be preferable to measure this activity directly. Our knowledge regarding the relevance of genetic Genetic analysis can be performed by different 
Mass spectrometry in SNP analysis:
The use of mass spectrometry for genotyping has been reviewed recently in detail 27,28 . Mass spectrometric methods are based on the determination of small mass changes of specific oligonucleotides that have been used to identify a SNP of interest. These oligonucleotides change their mass usually in a minisequencing reaction dependent on the genotype in the SNP analyzed. It is also possible to modify the oligonucleotide following the discriminatory reaction that way that the determination of the mass is much easier. Such oligonucleotides may be If genetic analysis is chosen, it usually requires the partially degraded or a specific mass-tag released. detection of known point mutations and rarely the analysis of whole genes for mutations. For most routine Mass spectrometry is an alternative to fluorescence-based and research purposes, the analysis of SNPs will be the technologies, can be automated, enables high-throughput major requirement for a laboratory 26 .
analysis and multiplexing. The result serves as quality control as well. The disadvantage may be that it is Single nucleotide polymorphism (SNP) analysis:
expensive and that the DNA-crystals needed for laserThe analysis of SNPs can either focus on single genes or mediated desorption, are not formed uniformly with on the combination and pattern of many SNPs. While the proteins. former is a simple straightforward approach that is based on the knowledge about the association of an SNP with
Fluorescence-based SNP analysis: gene function or specific phenotypes, the latter is a
The methods that do not rely on mass spectrometry and complicated approach that requires extensive clinical studies in most cases use fluorescence for detection can be on the clinical relevance of the combined genotypes. It is divided in six categories: i. Restriction digestion, ii. envisioned that upon identification of hundreds of Homogeneous hybridization, iii. Mismatch distinction by thousands of sequence variations within the genome polymerases and ligases, iv. Array hybridization assays, v. (human genome project) in the near future, simultaneous Minisequencing, and vi Rolling circle signal amplification. genetic analysis of the individual's DNA polymorphisms While all methods are useful for small sample series, real will be feasible. Technology is underway that will facilitate high-throughput analysis, as is needed for clinical trials, such massive parallel determinations in short time.
can be achieved only by some of the techniques. PCR can be performed on chips with on-board detection, Currently, a large number of molecular strategies are assays on micro particles and DNA-micro arrays. For being used for single nucleotide polymorphism (SNP) SNP analysis, specificity and discrimination of alleles is analysis 26 . In the majority of these methods, the target even of greater importance. Specificity of the amplification sequence is amplified and the polymorphism identified by process applies equally to any application and various technologies, for some of which multiplexing has methodology and is achieved by the use of two been demonstrated. In principle, there are two general approaches: mass spectrometry platforms and fluorescence-based platforms.
The distinction of the SNPs is either achieved by short hybridization probes or by restriction endonucleases, by discrimination of mismatched DNA substrates by polymerases or ligases or by observing the templatedependent choice of nucleotides incorporated by a polymerase (minisequencing). More recently, mass spectrometry (MALDI-TOF) has been demonstrated to be a good alternative. These various techniques have been adapted to assay formats that simplify scale-up in SNP analysis.
hybridizing events. Without amplification it is not possible to discriminate between alleles even if longer hybridization primers are used in combination with signal amplification procedures. Better discrimination of alleles is achieved with short primers.
Computational genomics:
Computational genomics can be defined as a discipline of computational biology, which deals with the analysis of entire genome sequences. But today, computational genomics is much more than mere sequence analysis. Although its roots lie in more traditional bioinformatics methods, there have been significant steps towards a more integral analysis of genome information, including 33 and genome organisation 34 . This increasingly intensified computational approach to genome analysis has generated not only tools for experimental biologists but also interesting scientific results 35 . homology is a subject of current research [64] [65] [66] [67] clear-cut rules may immediately apply. Second, the Gene finding:
transfer of this information, even when all other criteria There are two approaches for gene finding first is are satisfied, crucially depends on the quality of transient extrinsic approach 36 (searching protein databases with the database annotations 68 which may be far from satisfactory query DNA sequence for the identification of protein-(no published material on the quality control of curated coding genes) are not as effective as in the case of database annotations is available). Third, the prokaryotes. Even for prokaryotic genomes, reproducibility of sequence annotations is poor [69] [70] [71] [72] [73] inconsistencies of open reading frame calling abound 37 . the result is a conundrum of descriptions for genome Second is intrinsic approaches 36 of gene detection sequences without a clear consensus. (predicting genes from first principles such as exon/intron boundary detection) lack the appropriate amount of
The best annotations currently available take the form of learning sets for the training of the algorithms 38 Sequence analysis is fundamental for the characterisation of the query sequences, especially when no similarity to other sequences in the database is readily identifiable. In this category like the detection of coiled-coil 41 , trans membrane 42, 43 , cellular localization signal 44, 45 and compositionally biased 46, 47 regions.
Database searching:
The database search stage provides indications not only of family membership (when a set of sequences is identified as being homologous to the query sequence) but also of the possible function of the query sequence, when the homologues have been experimentally characterized and appropriately annotated [48] [49] [50] . New whole activity transcends the boundaries of 'classical' sequence analysis and necessitates technology that has yet to be developed. The idea is that the appropriately structured (and potentially formal) function descriptions of gene products can be integrated into systems that represent a general network of cellular processes, including metabolic pathways, transcription activation mechanisms and intracellular control cascades 77 . Metabolic databases 78 have formed a basis upon which other complex categorization schemes have been developed. Some of the most successful attempts here include various approaches to metabolic reconstruction, defined as the prediction of the metabolic complement for a species based on the analysis of genome sequence [79] [80] [81] [82] [83] [84] . www 90 or a more specific functional property 92 genomics, is sufficient to establish bioinformatics as an on the basis of their neighboring genes. Applications essential utility for the experimental biologists 85, 86 . include the comparative analysis of two bacterial Genome subtraction can only pick out unique genes if genomes 90 , the comparison of nine bacterial and archaeal the genome sequence is completely known. Wholegenomes to propose physical interactions of gene genome alignment requires entire genomes, almost by products 91 and the use of gene clusters from 31 complete definition. Finally, the precision performance of the last genomes to infer functional coupling and reconstruction two methods crucially relies on completeness 63 . Thus, all of metabolic networks 92 . the approaches described next can be defined as computational genomics methods according to our original Fusion analysis: Finally, based on the observation that the homologues of certain genes appear to fuse during the course of Genome subtraction: biological evolution, this approach attempts to predict Entire genomes allow the detection of unique sequences, functional association and protein interactions on the basis genes that are not present anywhere in the database or of gene fusion. The methods rely on the assumption that in the close relatives of the species under investigation 87 .
individual component proteins whose homologues are These elements are sometimes components of cellular involved in a fused, multi-domain protein must be pathways that remain to be discovered and can be involved with each other in a protein complex, interesting drug targets in pathogenic organisms. To biochemical pathway or another cellular process 62, 63 identify unique sequences, however, one has to detect Detection of false positive predictions by this approach is equivalent (or orthologous) genes, which are not always difficult, mainly due to the lack of extensive experimental easy to define 88 . Despite this shortcoming, this method information about protein interactions. will be most valuable for the comparison of bacterial strains or other, closely related species. Two interesting Towards a scientific discipline: studies using this virtual subtraction method have
The explosion in computational analysis methods for appeared for Haemophilus influenzae 87 and Helicobacter complete genomes brought out not only technologies but also some key scientific results. Some very interesting developments that have appeared in the recent literature Whole-genome alignment:
in the areas of metabolic reconstruction and comparative Another area where technical advances resulted in some genomics, using computation alone have been listed here. deeper understanding of the genome structure and thus function of certain species is whole-genome alignment 34 .
For metabolic reconstruction, examples include the Previous systems could not cope with hundreds of reconstruction of the metabolic networks of kilobases of raw DNA sequence. This advance will Methanococcus jannaschii 93 , the analysis of the facilitate detailed comparisons of genome organisation tricarboxylic acid cycle across a number of species 94 , the (revealing single nucleotide polymorphisms, translocations characterisation of the known metabolic complement of E. 103 , the derivation of the universal tree based on enzyme families 104 and the derivation of species relationships based on gene content 105 . www.ijpsonline.com
Taking a closer look at the properties of entire genome sequences, two things become apparent: first, comparative analysis greatly enhances our abilities to 'predict' and detect molecular function using sequence information and second, the current bottleneck in genomics appears to be the turnover of experimentally obtained novel properties for molecular families of unknown function. Once the function universe is covered, it may be that computation will acquire a truly central role in biological science.
Future directions:
roles for all genes and proteins. This is an immense task, made much more difficult by its nature as a community project. The amount of data is significant, but finite. It is the complexity of the information that makes this task daunting.
The issue of data complexity can be tackled by portable ontology designs, exact specifications of various conceptualizations for a given domain. This strategy is one way of dealing with highly complex, qualitatively rich features of specific domains of discourse. Such systems What is to be expected from computational genomics in the attempt to classify and further process various aspects of near future? As illustrated in the previous sections, our molecular function in terms of general hierarchies for battery of tools is becoming increasingly sophisticated and genome sequence and biochemical pathways, ribosome our ability to detect protein function using computation is structure and function, cellular processes and function generally improving. However, to resolve the issue of categories and generalized functional classes. Although function description and detection, we need to progress the latter are simple, general and also automatically from methods mostly derived from traditional sequence derived 106 , they have yet to be widely accepted. One analysis that examine genome sequences individually to reason may be the clash of opinions on the definition of algorithms and databases that exploit the inherent properties functional classes, and the relatively restricted utility of a of entire genomes. We are in the process of discovering high-precision but low-coverage classification of protein the constraints that apply to entire genomes so that functions 107 . genomic context can be reflected in our future methods, enhancing the quality of function descriptions.
Structural genomics:
The function of all proteins will be determined by the We argue here that all our approaches towards the sheer knowledge of their structure, a well-known motto in elusive goal of predicting function from sequence have structural biology [108] [109] [110] . Significant progress has already to take into account the genomic context and describe been made in terms of assigning structural homologues to molecular function in terms of actions and interactions proteins of known function for a number of completely within the cell. In other words, our procedures from sequenced species 111 . It should be noted, however, that sequence to function require the development of models some recent claims for structural genomics might be that describe cells as systems, using their genetic slightly overstated 112, 113 . blueprint, i.e., genome sequence.
By way of rising knowledge about interactions among Querying biological databases:
genes and drug treatment, there will be an equally It is indisputable that publicly available databanks play a increasing demand for speedy and consistent diagnostic fundamental role in disseminating sequence data to the tests prior to the institution of therapy. One can say that biological community. However, one of the most important problems of biological data repositories is their archive-like nature. Public databases are designed to store information in an unstructured way, largely in free-text flat-file format without defined object relations. This may help end-users that occasionally browse to retrieve individual entries, but it is very far from making the database amenable to largescale computation. In this sense, these repositories are not genuine database systems, designed for flexible querying and large-scale data mining.
Classifications of biological function:
To accurately describe function, biologists have to agree on a common vocabulary and classification of molecular analyzing genomes constitutes much more than mere sequence analysis, but it also includes essential characteristics of reaction detection and reconstruction of biological metabolism and therapeutics. Genome analysis is a highly consistent and dependable integration of functional information. However, one must clearly understand the fact that biological databases should exactly mimic the actual biological reality, as closely as possible, for this information to be useful for computation. ) .
